全文获取类型
收费全文 | 197326篇 |
免费 | 35644篇 |
国内免费 | 2636篇 |
专业分类
耳鼻咽喉 | 5653篇 |
儿科学 | 7147篇 |
妇产科学 | 3685篇 |
基础医学 | 10666篇 |
口腔科学 | 2233篇 |
临床医学 | 31173篇 |
内科学 | 57503篇 |
皮肤病学 | 8345篇 |
神经病学 | 20161篇 |
特种医学 | 7373篇 |
外科学 | 44747篇 |
综合类 | 518篇 |
现状与发展 | 73篇 |
一般理论 | 43篇 |
预防医学 | 11463篇 |
眼科学 | 4143篇 |
药学 | 4833篇 |
中国医学 | 138篇 |
肿瘤学 | 15709篇 |
出版年
2023年 | 5294篇 |
2022年 | 1565篇 |
2021年 | 4999篇 |
2020年 | 7267篇 |
2019年 | 3858篇 |
2018年 | 9176篇 |
2017年 | 8764篇 |
2016年 | 9981篇 |
2015年 | 10135篇 |
2014年 | 17717篇 |
2013年 | 18466篇 |
2012年 | 9841篇 |
2011年 | 9817篇 |
2010年 | 12564篇 |
2009年 | 16100篇 |
2008年 | 9050篇 |
2007年 | 7299篇 |
2006年 | 9437篇 |
2005年 | 6447篇 |
2004年 | 5518篇 |
2003年 | 4221篇 |
2002年 | 4082篇 |
2001年 | 3974篇 |
2000年 | 3139篇 |
1999年 | 3410篇 |
1998年 | 3856篇 |
1997年 | 3587篇 |
1996年 | 3489篇 |
1995年 | 3361篇 |
1994年 | 2104篇 |
1993年 | 1691篇 |
1992年 | 1441篇 |
1991年 | 1480篇 |
1990年 | 1110篇 |
1989年 | 1241篇 |
1988年 | 1076篇 |
1987年 | 893篇 |
1986年 | 939篇 |
1985年 | 769篇 |
1984年 | 625篇 |
1983年 | 578篇 |
1982年 | 585篇 |
1981年 | 455篇 |
1980年 | 415篇 |
1979年 | 336篇 |
1978年 | 358篇 |
1977年 | 433篇 |
1975年 | 297篇 |
1972年 | 293篇 |
1970年 | 263篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Alicia C. McDonald PhD MPH Jeremy Gernand PhD Nathaniel R. Geyer DrPH Hongke Wu MD MPH Yanxu Yang MPH Ming Wang PhD 《Cancer》2022,128(9):1832-1839
5.
Anna Maria Spera 《World Journal of Virology》2022,11(5):275-282
With a 5.3% of the global population involved, hepatitis B virus (HBV) is a major public health challenge requiring an urgent response. After a possible acute phase, the natural history of HBV infection can progress in chronicity. Patients with overt or occult HBV infection can undergo HBV reactivation (HBVr) in course of immunosuppressive treatments that, apart from oncological and hem-atological diseases, are also used in rheumatologic, gastrointestinal, neurological and dermatological settings, as well as to treat severe acute respiratory syndrome coronavirus 2 infection. The risk of HBV reactivation is related to the immune status of the patient and the baseline HBV infection condition. The aim of the present paper is to investigate the risk of HBVr in those not oncological settings in order to suggest strategies for preventing and treating this occurrence. The main studies about HBVr for patients with occult hepatitis B infection and chronic HBV infection affected by non-oncologic diseases eligible for immunosuppressive treatment have been analyzed. The occurrence of this challenging event can be reduced screening the population eligible for immunosuppressant to assess the best strategies according to any virological status. Further prospective studies are needed to increase data on the risk of HBVr related to newer immunomodulant agents employed in non-oncological setting. 相似文献
6.
7.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
8.
9.
10.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献